Sam Fazeli

But that is what biotech is.

And I have to say that I think Antoine is one of the most

optimistic people that I remember sitting on panels with, etc.

So it always was a pleasure to have those conversations.

We didn't always agree, but I think a lot of it was more for making the panels more interesting.

So where does Sofinova sit in the venture community in terms of approach?

What is special, if anything, about the group and in terms of the way you look at things?

Right, so when I look at these, Sophronova Capital is, for me at least, easy to understand.

I know what the idea is, biotech companies mostly, right?

Medical devices, I get that too.

Crossover, yeah, I get that.

We can talk about that in a minute, how the environment is for that particular area.

Industrial biotech, I think I get that.

So we're thinking, as you said, the application of biotechnology outside of developing medicines.

So the name that comes to my mind is Novozymes.

which is that kind of thing.

Am I right?

I mean, you can stop me each time and say, Sam, you're wrong.

And digital medicine is the one that I'm interested in why you separated that out.

I'm going to make a guess and you tell me if I'm stupid or not.